Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Harvard Business School
Mallinckrodt
Dow
McKinsey

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021656

See Plans and Pricing

« Back to Dashboard

NDA 021656 describes TRICOR, which is a drug marketed by Abbvie and Abbvie Inc and is included in three NDAs. It is available from eight suppliers. There are three patents protecting this drug and two Paragraph IV challenges. Additional details are available on the TRICOR profile page.

The generic ingredient in TRICOR is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.
Summary for 021656
Tradename:TRICOR
Applicant:Abbvie
Ingredient:fenofibrate
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 021656
Medical Subject Heading (MeSH) Categories for 021656
Suppliers and Packaging for NDA: 021656
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRICOR fenofibrate TABLET;ORAL 021656 NDA AbbVie Inc. 0074-3173 0074-3173-90 90 TABLET in 1 BOTTLE (0074-3173-90)
TRICOR fenofibrate TABLET;ORAL 021656 NDA AbbVie Inc. 0074-3189 0074-3189-90 90 TABLET in 1 BOTTLE (0074-3189-90)
Paragraph IV (Patent) Challenges for 021656
Tradename Dosage Ingredient NDA Submissiondate
TRICOR TABLET;ORAL fenofibrate 021656 2008-07-01
TRICOR TABLET;ORAL fenofibrate 021656 2007-10-19

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength48MG
Approval Date:Nov 5, 2004TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Sep 21, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
Patent:  Start TrialPatent Expiration:Feb 21, 2023Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Feb 21, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

Expired US Patents for NDA 021656

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004   Start Trial   Start Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004   Start Trial   Start Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004   Start Trial   Start Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004   Start Trial   Start Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004   Start Trial   Start Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004   Start Trial   Start Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKinsey
Dow
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.